Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 263-174-9 | CAS number: 61791-42-2
No studies adressing toxicokinetics are available for the test substance. However, structure related consideration suggests enzymatic degradation in analogy to accepted metabolic pathways for amide hydrolysis and fatty acid ß-oxidation. The metabolism will not generate metabolites of toxicological concern. Excretion of postulated metabolites is considered fast and complete. Due to its solid state, the moderate molecular weight close to 500 and the ionic nature, only limited dermal penetration is expected.
There are no experimental studies available investigating the toxicokinetic properties of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts. Therefore, whenever possible, toxicokinetic behavior was assessed taking into account the available information on physico-chemical and toxicological characteristics of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts according to the “Guidance on information and chemical safety assessment Chapter R.7c: Endpoint specific guidance (ECHA, 2017)”.
Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts is a UVCB substance and has a molecular weight of 287.4 -427.6 g/mol. It is a white solid powder with a moderate to high water solubility (0.23 – 250 g/L), a vapour pressure of < 1 Pa at 25 °C and a log Pow of -0.44 - 0.54.
The molecular weight, the water solubility and the moderate log Pow value favour an absorption along the gastrointestinal tract. The acute oral toxicity study of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts and also of the read-across substance Sodium 2-[methyloleoylamino]ethane-1-sulphonate has been investigated in rats (Clariant, 1987a and 1987b). The LD50 from these studies was determined to be > 2000 mg/kg bw for male and female animals, respectively. As a number of clinical signs of toxicity were observed following dose administration, it can be assumed that a certain amount of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts must have been absorbed.
The particle size determination of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts revealed percentile values of D10: 3.87 µm, D50: 16.58 µm and D90: 59.97 µm. Particles with and aerodynamic diameter below 100 µm have the potential to be inhaled and may reach the thoracic region of the respiratory tract if they are < 50 µm and the alveolar region if they are < 15 µm. Therefore, inhalation of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts is generally possible. However, since the substance is a solid with a very low vapour pressure (<1 Pa at 25 °C), it is probably not available for inhalation as vapour. Furthermore, the use of the substance is not anticipated to result in the formation of aerosols, particles or droplets of inhalable size. Thus, exposure of humans via inhalation is unlikely.
Regarding the water solubility (0.23 - 250 g/L) and the lipophilic properties of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts (log Pow -0.44 - 0.54), dermal absorption is anticipated to be generally possible. However, due to its solid state and the moderate molecular weight close to 500 g/mol, dermal uptake is overall considered to be low. This result is underpinned by a Dermwin v2.0 QSAR modeling which estimated a dermal permeability constant Kp 9.38E- 006 cm/h for Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts. The maximum flux Imax (Imax = Kp [cm/h] x water solubility [mg/cm³]) was calculated, resulting in dermal absorption of 0.002 and 2.345 µg substance/cm²/h.
Distribution within the body depends on the molecular weight, the lipophilic character and water solubility of a substance. In general, the smaller the molecule, the wider is the distribution. If the molecule is lipophilic, it is likely to distribute into cells and the intracellular concentration may be higher than extracellular concentration particularly in fatty tissues (ECHA, 2017). With a molecular weight of 287.4 - 427.6 g/mol and the slight lipophilic character (log Pow > 0), Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts is considered to distribute within the body and to enter particularly fatty tissues to a certain but low extent.
Metabolism and Excretion
Following the accepted metabolic pathways for alkylamides, the amide linkage of Ethanesulfonic acid, 2-(methylamino)-, N-coco acyl derivs., sodium salts will initially be hydrolysed to generate sodium N-methyl taurine and fatty acids by fatty acid amide hydrolase, the principal catabolic enzyme for fatty acid amides having both, esterase and amidase activity (EPA, 2009). This metabolism step was also observed after modeling of potential metabolites with the hydrolysis simulator of the OECD toolbox Vs. 3.2. The resulting anionic sulfonate may be either directly excreted in the urine or converted to a dianionic salt with glucuronic acid that is excreted. The fatty acid moiety is metabolised in a second step via the ß-oxidation pathway (Stryer, 1996). This metabolic behaviour was also demonstrated for sodium N-oleoyl-N-methyltaurine in Pseudomonas alcaligenes (Denger et al. 2008).
Denger, K., Mayer, J., Hollemeyer, K., Cook, A.M. (2008), FEMS Microbiol. Lett. 288: 112- 117
ECHA (2017). Guidance on information requirements and chemical safety assessment, Chapter R.7c: Endpoint specific guidance. Version 3.0.
EPA (2009), Final Rule, Federal Register 74, 2009 [EPA-HQ-OPP-2008-0725; FRL-8426-8]
Stryer, L. (1996). Biochemie. 4. Auflage. Heidelberg Berlin Oxford: Spektrum Akademischer Verlag
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again